The diabetes community recently gathered at the 82nd Scientific Sessions of the ADA to share the latest developments in diabetes care and medicine. Kidney health generated some buzz during the five day conference along with the newly FDA-approved anti-obesity drug tirzepatide.

Tracking and managing kidney health is notoriously difficult.

Established testing and monitoring practices reveal diminished kidney function only after it’s become substantial. Beyond this, current screening methods (using blood and urine analysis) yield only a broad-brush reading of the mechanisms that drive kidney disease, resulting in treatment approaches that lack precision and personalization.

NaviDKD™ proactive screening technology for kidney health from Journey Biosciences confirmed in type 2 diabetes population.

A groundbreaking study just published in Diabetes Care confirms that tracking a panel of predictive biomarkers, advanced glycation end products (AGEs), can reveal a person’s risk level for developing kidney complications with type 2 diabetes, supporting precision medicine when addressing kidney health.

As National Kidney Month 2022 winds up we’re taking a few minutes to recap and reflect on a few recent encouraging news stories and events in kidney health.

There’s no denying that treatment options for diabetes have expanded over recent decades. With all the focus on improving glycemic management, it’s easy to understand why improvements in kidney care may have flown under the radar.

While the risk of developing chronic kidney disease is high for people with diabetes, that risk can be reduced through the use of proactive health checks in combination with preventative care.

Kidney disease is among the most devastating diabetes complications. It’s difficult to diagnose, which means it’s often discovered only after substantial damage to the kidneys has already been done and few effective treatment options remain. We’re working on changing this scenario.

Journey Biosciences adds two accomplished independent directors with deep roots in the diabetes industry to its board to coincide with its recent commercial launch.

Journey Biosciences, Inc. today announced a collaboration with Cardinal Health OptiFreight® Logistics that will increase control and visibility across every transportation modality.

In this interview, Journey Biosciences CEO Adam Graybill shares his experience working in the “complicated diabetes space,” and what exactly inspired him to create this novel testing company that’s focused on elevating customer service.

Journey Biosciences' NaviDKD diagnostic screening technology ensures health care professionals and people with diabetes have the necessary tools to proactively improve their diabetes care.